Circle reported a 17% increase in Q3 revenue to $865 million and a 5% rise in net income to $226 million, driven largely by a $182 million ARC token presale. This new revenue stream helped offset an 8% decline in income from USDC reserves. The company also cut its workforce by 5%, incurring $9.15 million in restructuring costs, as it aligns with strategic priorities. Circle is expanding beyond stablecoin reserve income with the ARC token and growing its payments network, signaling a shift toward diversified crypto revenue sources.
Circle's Q3 financial results provide context for readers following crypto market trends. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Nov 04, 2026 21:23 WIB: out of 50 priced assets, 30 rose and 19 fell. Notable movers include BAL at Rp16.297 with an 11.14% increase, BAT at Rp2.507 rising 9.25%, and EOS at Rp12.649 up 8.13%.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
